- Three abstracts demonstrate new insights that can be derived from whole-transcriptome-based thyroid cancer molecular profiles - SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 21, 2023-- Veracyte, Inc. (Nasdaq: VCYT) today announced that three posters showcasing new data from the company’s
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 7, 2023-- Veracyte, Inc. (Nasdaq: VCYT) announced that Marie-Claire Taine , Ph.D., will join Veracyte as general manager of the company’s in vitro diagnostics (IVD) Business Unit, based in Marseille, France .
Partnership will leverage Gustave Roussy’s tumor samples and Veracyte’s Biopharma Atlas multi-omic database and machine learning capabilities SOUTH SAN FRANCISCO, Calif. & PARIS--(BUSINESS WIRE)--Sep. 6, 2023-- Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company, and Gustave Roussy , a
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 29, 2023-- Veracyte, Inc . (Nasdaq: VCYT) announced today that Marc Stapley , chief executive officer, and Rebecca Chambers , chief financial officer, will participate in a fireside chat at the Morgan Stanley 21 st Annual Global Healthcare
New data are from a retrospective analysis of the Phase 2 STREAM trial SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 22, 2023-- Veracyte, Inc . (Nasdaq: VCYT) announced that new data published in JCO Precision Oncology suggest that gene expression signatures derived from the company’s
Awards mark Veracyte’s 10 th consecutive honor in the Bay Area and inaugural recognition in San Diego SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 15, 2023-- Veracyte, Inc . (Nasdaq: VCYT) announced that its South San Francisco and San Diego offices have been named top workplaces.
Grew Total Revenue to $90.3 million , an Increase of 24% Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 8, 2023-- Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the second quarter ended June 30, 2023 .
Clinical utility study findings based on analysis of the National Cancer Institute’s SEER database SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 1, 2023-- Veracyte, Inc . (Nasdaq: VCYT) announced the publication of a large, real-world study reinforcing the Decipher Prostate Genomic
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 19, 2023-- Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the second quarter of 2023 after the close of market on Tuesday, August 8, 2023 . Company management will host a conference call and webcast to
Findings presented at ENDO 2023 also confirm analytical validity of company’s TERT promoter gene mutation testing for thyroid nodule patients SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jun. 20, 2023-- Veracyte, Inc . (Nasdaq: VCYT) announced that new data presented at ENDO 2023, the annual
The information in our press releases and webcasts should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these press releases or presentations.
